The proportion of patients with mean potassium < 5.1 mEq/L during days 8-29 was significantly higher in all zirconium cyclosilicate groups vs placebo ( 36/45 [ 80 % ] , 45/50 [ 90 % ] , and 51/54 [ 94 % ] for the 5-g , 10-g , and 15-g groups , vs 38/82 [ 46 % ] with placebo ; P < .001 for each dose vs placebo ) .